+44 (0) 1223 755950
+1 832 327 7413
Click on the image to see the image legend
Target | Von Hippel-Lindau Disease Tumor Suppressor (VHL) |
Clonality | Polyclonal |
Reactivity | Human, Mouse |
Tested Applications | ELISA, WB, IHC, IF/ICC, FCM |
Host | Rabbit |
Recommended dilutions | WB: 1/2000, IHC-P: 1/25, IF/ICC: 1/25, FCM: 1/25. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user. |
Conjugation | Unconjugated |
Immunogen | KLH-conjugated synthetic peptide between 43-71 amino acids from the N-terminal region of human VHL. |
Isotype | IgG |
Form | Liquid |
Purification | Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
UniProt Primary AC | P40337 (UniProt, ExPASy) |
UniProt Secondary AC | B2RE45, Q13599, Q6PDA9 |
UniProt Entry Name | VHL_HUMAN |
NCBI Accession | NP_000542.1 NP_937799.1 |
KEGG | hsa:7428 |
String | 9606.ENSP00000256474 |
Molecular Weight | Calculated MW: 24.2 kDa |
Buffer | PBS containing 0.09% sodium azide. |
Specificity | Predicted to react with Rat VHL. |
Availability | Shipped within 5-10 working days. |
Note | This product is for research use only. |